Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells
J Reiffers, C Cailliot, B Dazey, M Attal, J Caraux… - The Lancet, 1999 - thelancet.com
J Reiffers, C Cailliot, B Dazey, M Attal, J Caraux, JM Boiron
The Lancet, 1999•thelancet.comWe show that absolute and severe neutropenia after high-dose therapy with melphalan with
or without total body irradiation can be abrogated by cells generated ex vivo. This may
change the clinical practice of haematopoietic cell transplantation and high-dose
chemotherapy because the morbidity and hospitalisation associated with neutropenia could
be avoided or reduced.
or without total body irradiation can be abrogated by cells generated ex vivo. This may
change the clinical practice of haematopoietic cell transplantation and high-dose
chemotherapy because the morbidity and hospitalisation associated with neutropenia could
be avoided or reduced.
Summary
We show that absolute and severe neutropenia after high-dose therapy with melphalan with or without total body irradiation can be abrogated by cells generated ex vivo. This may change the clinical practice of haematopoietic cell transplantation and high-dose chemotherapy because the morbidity and hospitalisation associated with neutropenia could be avoided or reduced.
thelancet.com